Company
LON:AVCT
At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets. Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.
207 stories · page 5 of 11
Investments and investor services
The Week Ahead will also bring trading updates from the likes of Vodafone, Anglo American, William Hill, Dixons Carphone, and WH Smith, plus the latest UK jobs and wages data
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
The FTSE 100 recovered in afternoon trading and closed up six points at 6,734
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Dr Josep Tabernero, President of the European Society for Medical Oncology and Head of the Val d'Hebron Institute of Oncology, Barcelona, will give the plenary presentation
Archive
At the close, the FTSE 100 was down 71.93 points, or 1.1% at 6,773.24, just above the session low of 6,761.37 and well below the early high of 6,845.17.
Some of the main news-driven risers and fallers in London on Wednesday...
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Dr Jose Saro is joining the business from the Roche Innovation Center
The benchmark index also gets a boost from optimism over US-China trade talks
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A look at the day's major movers, including Local Shopping REIT, Just Group, Photo-Me, Lb-Shell, Avacta and ValiRx
The Affimer technology is Avacta's proprietary alternative to antibodies with wide applications in the life sciences for drug development, diagnostics and research tools
Investments and investor services
The UK premier index finished down around 56 points at 6,721 on Monday
The deal with New England Biolabs, signed in October, is expected to secure six-figure royalty sums as soon as next year
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
A look at the day's winners and sinners, including Dignity, Online Blockchain, Restaurant Group, TomCo Energy, Johnston Press, GYG, Anglo African Agriculture and Carr's Group
